Valuation : CEL-SCI Corporation

Market Cap 2.81Cr 2.43Cr 2.27Cr 2.08Cr 3.91Cr 268.97Cr 3.92Cr 27Cr 11Cr 135.77Cr 11Cr 10Cr 450.2Cr P/E 2026 *
-0.52x
P/E 2027 * -0.25x
Enterprise Value 2.26Cr 1.95Cr 1.82Cr 1.67Cr 3.14Cr 215.89Cr 3.15Cr 22Cr 8.45Cr 108.98Cr 8.48Cr 8.3Cr 361.35Cr EV / Sales 2026 *
-
EV / Sales 2027 * 3.82x
Free-Float
93.73%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 67 01/01/1995
Director of Finance/CFO 75 13/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2024
Director TitleAgeSince
Director/Board Member 67 01/01/1995
Director/Board Member 73 22/06/2015
Chairman 69 08/07/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%-14.33% - - 2.81Cr
-1.59%-6.25%+64.99%+99.09% 7.06TCr
-1.34%+1.13%+47.33%+90.79% 6.61TCr
-7.89%-11.65%+1.04%-14.66% 2.8TCr
-2.49%-5.63%-12.06%+448.98% 2.65TCr
+0.30%+2.03%+59.48%+14.21% 2.64TCr
-0.96%+12.36%+280.38%+439.54% 2.04TCr
-0.51%+0.23%+33.71%-18.02% 2.02TCr
-1.91%-3.47%+11.03%+508.52% 1.6TCr
-1.36%+0.92%+44.00%+146.06% 1.37TCr
Average -1.82%+1.12%+58.88%+190.50% 3.2TCr
Weighted average by Cap. -1.95%+1.23%+56.20%+151.45%

Financials

2026 *2027 *
Net sales - 59.72L 51.46L 48.25L 44.04L 82.97L 57Cr 83.24L 5.72Cr 2.23Cr 29Cr 2.24Cr 2.19Cr 96Cr
Net income -2.51Cr -2.16Cr -2.03Cr -1.85Cr -3.49Cr -239.74Cr -3.5Cr -24Cr -9.38Cr -121.02Cr -9.42Cr -9.21Cr -401.28Cr -2.95Cr -2.54Cr -2.38Cr -2.18Cr -4.1Cr -282.08Cr -4.11Cr -28Cr -11Cr -142.39Cr -11Cr -11Cr -472.14Cr
Net Debt -55.54L -47.86L -44.87L -40.96L -77.17L -53Cr -77.41L -5.32Cr -2.08Cr -27Cr -2.09Cr -2.04Cr -89Cr -53.39L -46.01L -43.14L -39.38L -74.18L -51Cr -74.41L -5.12Cr -2Cr -26Cr -2Cr -1.96Cr -85Cr
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-